Voyager Therapeutics Announces Third Quarter 2024 Conference Call and Webcast

VYGR 11.05.2024

Full Press ReleaseSEC FilingsOur VYGR Tweets

About Gravity Analytica

Recent News

  • 01.13.2025 - Pete Stavropoulos
  • 12.03.2024 - Samantha Semenkow, Ph.D.
  • 11.20.2024 - Voyager Selects Tau Silencing Gene Therapy Development Candidate for Alzheimer’s Disease

Recent Filings

  • 01.15.2025 - 4 Statement of changes in beneficial ownership of securities
  • 01.14.2025 - 144 Report of proposed sale of securities
  • 11.14.2024 - SC 13G/A Statement of Beneficial Ownership by Certain Investors

LEXINGTON, Mass.,Nov. 05, 2024(GLOBE NEWSWIRE) --Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced it will report third quarter 2024 financial and operating results after market close on Tuesday, November 12, 2024. Subsequently, the Company will host a conference call and webcast at 4:30 p.m. ET.

A live webcast of the call will be available on the Investors section of the Voyager website atir.voyagertherapeutics.com, and a replay of the call will be available at the same link approximately two hours after its completion. The replay will be available for at least 30 days following the conclusion of the call.

About Voyager TherapeuticsVoyager Therapeutics, Inc. (Nasdaq: VYGR) is a biotechnology company dedicated to leveraging the power of human genetics to modify the course of – and ultimately cure – neurological diseases. Our pipeline includes programs for Alzheimer’s disease, amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and multiple other diseases of the central nervous system. Many of our programs are derived from our TRACERTM AAV capsid discovery platform, which we have used to generate novel capsids and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous dosing. Some of our programs are wholly owned, and some are advancing with partners including Alexion, AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc.; and Sangamo Therapeutics, Inc. For more information, visitwww.voyagertherapeutics.com.

Voyager Therapeutics®is a registered trademark, and TRACERTM is a trademark, of Voyager Therapeutics, Inc.

Contacts

Trista Morrison, NACD.DC,tmorrison@vygr.comInvestors: Mike Hencke,mhencke@kendallir.comMedia: Brooke Shenkin,brooke@scientpr.com

Primary Logo

Source: Voyager Therapeutics, Inc.

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com